Back HIV/AIDS

HIV / AIDS

FDA Approves Complera as Switch Option for People with Suppressed HIV

The U.S. Food and Drug Administration this month expanded the indication for the single-tablet regimen Complera (rilpivirine/tenofovir/emtricitabine, known as Eviplera in Europe). The 3-in-1 combination pill is now approved for people with suppressed viral load who wish to switch regimens.

alt

FDA Approves Complera as Switch Option for People with Suppressed HIV

TEXT

alt

Nutritional Supplements Beneficial for HIV+ People Who Do Not Yet Need ART

HIV positive people with CD4 cell counts above 350 cells/mm3 who have not yet started antiretroviral therapy (ART) may reduce their risk of disease progression, immune system decline, and death if they take a multivitamin and selenium supplement, according to a study from Botswana published in the November 27, 2013, issue of JAMA.

alt

Severe Seroconversion Symptoms Predict Faster HIV Disease Progression

People who experience more severe symptoms or who have lower CD4 T-cell counts when they first become infected with HIV are more likely to experience faster disease progression later on, according to an international study described in the November 14, 2013, edition of PLoS Medicine.

alt

San Francisco Forum Discusses Condomless Sex and HIV Prevention

A standing-room-only crowd packed the house at Magnet in San Francisco's Castro district on December 3 for a Real Talk discussion about condomless sex and HIV prevention. A panel of community members and medical experts considered questions such as: Why do gay and bisexual men have condom-free sex? Are community attitudes around condom use changing? and How do treatment as prevention and pre-exposure prophylaxis (PrEP) factor into the equation?

alt

BMS Licenses Atazanavir to Medicines Patent Pool, Allowing Cheaper Generics

Bristol-Myers Squibb and the Medicines Patent Pool have reached a licensing agreement that will enable generic drug manufacturers to produce inexpensive versions of the HIV protease inhibitor atazanavir (Reyataz), as well as fixed-dose combinations containing the drug, for use in low-income countries, MPP recently announced. It is the first MPP agreement to cover a preferred second-line therapy.

alt

IDSA Issues New Guidelines for Vaccination of Immune-compromised People

The Infectious Diseases Society of America (IDSA) this month released new recommendations for vaccinations for people with HIV and other immune-compromising conditions. The guidelines were published in the December 4, 2013, advance edition of Clinical Infectious Diseases.

alt